A Randomized Study of Sulindac in Oral Premalignant Lesions
Status:
Completed
Trial end date:
2020-01-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a drug called sulindac can prevent the development of
changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia)
or oral cancer. Sulindac is an anti-inflammatory drug that has already been tested in people
with arthritis (inflammation of a joint).
This study is being done by Memorial Sloan-Kettering Cancer Center in New York, Amrita
Institute of Medical Sciences and Research Center in Cochin, India, and Regional Cancer
Centre (RCC) in Trivandrum, India.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Amrita Institute of Sciences, AIMS, Cochin, India Narayana Hrudayalaya Hospitals Regional Cancer Center(RCC), Trivandrum, India Weill Medical College of Cornell University